Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1644
This examiner grants 60% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18046865 | METHODS FOR ASSAYING T-CELL DEPENDENT BISPECIFIC ANTIBODIES | Non-Final OA | Genentech, Inc. |
| 17775386 | Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules | Non-Final OA | AMGEN INC. |
| 18106567 | CD6 ANTIBODY FOR TREATMENT OF T-CELL MEDIATED DISEASES OR DISORDERS | Non-Final OA | The Regents of the University of Michigan |
| 18052746 | METHOD FOR PRODUCING ANTIBODY | Non-Final OA | SYSMEX CORPORATION |
| 17436929 | T CELL RECEPTORS AND METHODS OF USE THEREOF | Non-Final OA | University Health Network |
| 16958539 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASE | Final Rejection | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. |
| 18168192 | COMPOSITIONS FOR INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION | Non-Final OA | Omeros Corporation |
| 18152536 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation | Non-Final OA | Omeros Corporation |
| 16702996 | BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 | Final Rejection | GENMAB A/S |
| 18355871 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation | Non-Final OA | University of Leicester |
| 17814205 | IMMUNOGENIC WT-1 PEPTIDES AND METHODS OF USE THEREOF | Final Rejection | Memorial Sloan Kettering Cancer Center |
| 17848313 | SYSTEMS AND METHODS FOR TARGETING CANCER CELLS | Non-Final OA | The Simons Foundation, Inc. |
| 17958995 | ANTI-CD3 ANTIBODY AND PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT COMPRISING SAME | Non-Final OA | Mogam Institute For Biomedical Research |
| 17898208 | ANTI-BCMA HEAVY CHAIN-ONLY ANTIBODIES | Final Rejection | TeneoOne, Inc. |
| 16586318 | CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS | Final Rejection | AMGEN RESEARCH (MUNICH) GMBH |
| 17128570 | T CELL RECRUITING POLYPEPTIDES BASED ON TCR ALPHA/BETA REACTIVITY | Final Rejection | Ablynx N.V. |
| 17298903 | METHODS FOR SELECTIVE IN VIVO EXPANSION OF GAMMA DELTA T-CELL POPULATIONS AND COMPOSITIONS THEREOF | Final Rejection | ADICET THERAPEUTICS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy